Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults in the US. Management of atopic dermatitis can create burdens for the family, and the disorder can decrease quality of life. Itching, in particular, can disrupt sleep and lead to daytime sleepiness, irritability, and psychological stress, and cosmetically important lesions can lead to social stress and isolation.
ICER’s report will evaluate the comparative clinical effectiveness and value of two emerging therapies for atopic dermatitis: crisaborole and dupilumab. Crisaborole will be evaluated based on its expected indication in the treatment of mild-to-moderate atopic dermatitis in children and adults; separately, dupilumab will be evaluated for its expected indication in the treatment of moderate-to-severe atopic dermatitis in adults.
Interventions of Interest:
- Crisaborole (Eucrisa™, Pfizer, Inc.)
- Dupilumab (Dupixent®, Sanofi and Regeneron, Inc.)
Date of Review: May 2017
For questions or additional information, please contact email@example.com
University of Chicago Gleacher Center at the Booth School of Business
450 N Cityfront Plaza Drive
Chicago, IL 60611
The Midwest CEPAC convened in May 2017 to discuss ICER's report on dupilumab and crisaborole for atopic dermatitis.
Public comment on draft scoping document.
Public comment period on draft evidence report and draft voting questions.